In the SILCAAT research, the position of the principal end point was unknown for 91 of the 849 patients receiving interleukin-2 and antiretroviral therapy and for 100 of the 846 patients receiving antiretroviral therapy alone. In ESPRIT, the status of the primary end point was unknown for 118 of the 2071 patients receiving interleukin-2 and antiretroviral therapy and for 134 of the 2040 individuals receiving antiretroviral therapy alone. Usage of Interleukin-2 In the SILCAAT research, 72.3 percent of individuals receiving interleukin-2 plus antiretroviral therapy completed six cycles of interleukin-2 therapy; 2.1 percent never received interleukin-2.The therapeutic effect that was seen with mepolizumab treatment shows how we can find out more about the pathogenesis of different airway responses by studying selective inhibitors of inflammation. The patients who were included in this scholarly study acquired refractory eosinophilic asthma despite optimum tolerated therapy, which oftentimes included regular use of oral corticosteroids. Their asthma resembled the exacerbation-prone phenotype of severe asthma, as explained by Moore et al.,19 and the phenotype of asthma with predominant eosinophilic swelling, which we’ve described.20 Our effects should not be extrapolated beyond the highly selected group of individuals we recruited because of this study.